Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Unexplained exertional intolerance associated with impaired systemic oxygen extraction.

Melamed KH, Santos M, Oliveira RKF, Urbina MF, Felsenstein D, Opotowsky AR, Waxman AB, Systrom DM.

Eur J Appl Physiol. 2019 Sep 6. doi: 10.1007/s00421-019-04222-6. [Epub ahead of print]

PMID:
31493035
2.

Dynamic right ventricular-pulmonary arterial uncoupling during maximum incremental exercise in exercise pulmonary hypertension and pulmonary arterial hypertension.

Singh I, Rahaghi FN, Naeije R, Oliveira RKF, Vanderpool RR, Waxman AB, Systrom DM.

Pulm Circ. 2019 Jul-Sep;9(3):2045894019862435. doi: 10.1177/2045894019862435.

3.

Pulmonary Vascular Distensibility and Early Pulmonary Vascular Remodeling in Pulmonary Hypertension.

Singh I, Oliveira RKF, Naeije R, Rahaghi FN, Oldham WM, Systrom DM, Waxman AB.

Chest. 2019 May 20. pii: S0012-3692(19)31063-3. doi: 10.1016/j.chest.2019.04.111. [Epub ahead of print]

PMID:
31121149
4.

Right Ventricular-Arterial Uncoupling During Exercise in Heart Failure With Preserved Ejection Fraction: Role of Pulmonary Vascular Dysfunction.

Singh I, Rahaghi FN, Naeije R, Oliveira RKF, Systrom DM, Waxman AB.

Chest. 2019 May 16. pii: S0012-3692(19)31057-8. doi: 10.1016/j.chest.2019.04.109. [Epub ahead of print]

PMID:
31103695
5.

Anatomic Relationship of the Complex Tricuspid Valve, Right Ventricle, and Pulmonary Vasculature: A Review.

Hahn RT, Waxman AB, Denti P, Delhaas T.

JAMA Cardiol. 2019 May 1;4(5):478-487. doi: 10.1001/jamacardio.2019.0535.

PMID:
30994879
6.

Perfusion Imaging Distinguishes Exercise Pulmonary Arterial Hypertension at Rest.

Kohli P, Kelly VJ, Kehl EG, Rodriguez-Lopez J, Hibbert KA, Kone M, Systrom DM, Waxman AB, Venegas JG, Channick R, Winkler T, Harris RS.

Am J Respir Crit Care Med. 2019 Jun 1;199(11):1438-1441. doi: 10.1164/rccm.201810-1899LE. No abstract available.

PMID:
30811948
7.

BOLA (BolA Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension.

Yu Q, Tai YY, Tang Y, Zhao J, Negi V, Culley MK, Pilli J, Sun W, Brugger K, Mayr J, Saggar R, Saggar R, Wallace WD, Ross DJ, Waxman AB, Wendell SG, Mullett SJ, Sembrat J, Rojas M, Khan OF, Dahlman JE, Sugahara M, Kagiyama N, Satoh T, Zhang M, Feng N, Gorcsan J 3rd, Vargas SO, Haley KJ, Kumar R, Graham BB, Langer R, Anderson DG, Wang B, Shiva S, Bertero T, Chan SY.

Circulation. 2019 May 7;139(19):2238-2255. doi: 10.1161/CIRCULATIONAHA.118.035889.

PMID:
30759996
8.

The Tricuspid Valve Relationship With the Right Ventricle and Pulmonary Vasculature.

Hahn RT, Delhaas T, Denti P, Waxman AB.

JACC Cardiovasc Imaging. 2019 Mar;12(3):564-565. doi: 10.1016/j.jcmg.2018.11.016. Epub 2019 Jan 16. No abstract available.

PMID:
30660539
9.

Ultrasound-assisted catheter-directed thrombolysis compared with anticoagulation alone for treatment of intermediate-risk pulmonary embolism.

Schissler AJ, Gylnn RJ, Sobieszczyk PS, Waxman AB.

Pulm Circ. 2018 Oct-Dec;8(4):2045894018800265. doi: 10.1177/2045894018800265. Epub 2018 Aug 24.

10.

NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension.

Samokhin AO, Stephens T, Wertheim BM, Wang RS, Vargas SO, Yung LM, Cao M, Brown M, Arons E, Dieffenbach PB, Fewell JG, Matar M, Bowman FP, Haley KJ, Alba GA, Marino SM, Kumar R, Rosas IO, Waxman AB, Oldham WM, Khanna D, Graham BB, Seo S, Gladyshev VN, Yu PB, Fredenburgh LE, Loscalzo J, Leopold JA, Maron BA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaap7294. doi: 10.1126/scitranslmed.aap7294.

11.

The Dyspnea Clinic.

Ryan JJ, Waxman AB.

Circulation. 2018 May 8;137(19):1994-1996. doi: 10.1161/CIRCULATIONAHA.117.029769. No abstract available.

PMID:
29735586
12.

Right ventriculo-arterial uncoupling and impaired contractile reserve in obese patients with unexplained exercise intolerance.

McCabe C, Oliveira RKF, Rahaghi F, Faria-Urbina M, Howard L, Axell RG, Priest AN, Waxman AB, Systrom DM.

Eur J Appl Physiol. 2018 Jul;118(7):1415-1426. doi: 10.1007/s00421-018-3873-4. Epub 2018 Apr 30.

13.

Rationale and design of the ranolazine PH-RV study: a multicentred randomised and placebo-controlled study of ranolazine to improve RV function in patients with non-group 2 pulmonary hypertension.

Han Y, Forfia PR, Vaidya A, Mazurek JA, Park MH, Ramani G, Chan SY, Waxman AB.

Open Heart. 2018 Feb 23;5(1):e000736. doi: 10.1136/openhrt-2017-000736. eCollection 2018.

14.

Network Analysis to Risk Stratify Patients With Exercise Intolerance.

Oldham WM, Oliveira RKF, Wang RS, Opotowsky AR, Rubins DM, Hainer J, Wertheim BM, Alba GA, Choudhary G, Tornyos A, MacRae CA, Loscalzo J, Leopold JA, Waxman AB, Olschewski H, Kovacs G, Systrom DM, Maron BA.

Circ Res. 2018 Mar 16;122(6):864-876. doi: 10.1161/CIRCRESAHA.117.312482. Epub 2018 Feb 5.

15.

Impaired systemic oxygen extraction in treated exercise pulmonary hypertension: a new engine in an old car?

Faria-Urbina M, Oliveira RKF, Segrera SA, Lawler L, Waxman AB, Systrom DM.

Pulm Circ. 2018 Jan-Mar;8(1):2045893218755325. doi: 10.1177/2045893218755325. Epub 2018 Jan 8.

16.

Inhaled Treprostinil in Pulmonary Hypertension Associated with Lung Disease.

Faria-Urbina M, Oliveira RKF, Agarwal M, Waxman AB.

Lung. 2018 Apr;196(2):139-146. doi: 10.1007/s00408-017-0081-7. Epub 2017 Dec 23.

PMID:
29275453
17.

A four-tier classification system of pulmonary artery metrics on computed tomography for the diagnosis and prognosis of pulmonary hypertension.

Truong QA, Bhatia HS, Szymonifka J, Zhou Q, Lavender Z, Waxman AB, Semigran MJ, Malhotra R.

J Cardiovasc Comput Tomogr. 2018 Jan - Feb;12(1):60-66. doi: 10.1016/j.jcct.2017.12.001. Epub 2017 Dec 6.

PMID:
29254655
18.

Pulmonary Vascular Resistance During Exercise Predicts Long-Term Outcomes in Heart Failure With Preserved Ejection Fraction.

Huang W, Oliveira RKF, Lei H, Systrom DM, Waxman AB.

J Card Fail. 2018 Mar;24(3):169-176. doi: 10.1016/j.cardfail.2017.11.003. Epub 2017 Nov 24.

PMID:
29180305
19.

Assessment of the quality of anticoagulation management in patients with pulmonary arterial hypertension.

Roldan T, Villamañán E, Rios JJ, Waxman AB.

Thromb Res. 2017 Dec;160:83-90. doi: 10.1016/j.thromres.2017.10.024. Epub 2017 Nov 2.

PMID:
29127864
20.

PVDOMICS: A Multi-Center Study to Improve Understanding of Pulmonary Vascular Disease Through Phenomics.

Hemnes AR, Beck GJ, Newman JH, Abidov A, Aldred MA, Barnard J, Berman Rosenzweig E, Borlaug BA, Chung WK, Comhair SAA, Erzurum SC, Frantz RP, Gray MP, Grunig G, Hassoun PM, Hill NS, Horn EM, Hu B, Lempel JK, Maron BA, Mathai SC, Olman MA, Rischard FP, Systrom DM, Tang WHW, Waxman AB, Xiao L, Yuan JX, Leopold JA; PVDOMICS Study Group.

Circ Res. 2017 Oct 27;121(10):1136-1139. doi: 10.1161/CIRCRESAHA.117.311737. No abstract available.

21.

Functional impact of exercise pulmonary hypertension in patients with borderline resting pulmonary arterial pressure.

Oliveira RKF, Faria-Urbina M, Maron BA, Santos M, Waxman AB, Systrom DM.

Pulm Circ. 2017 Jul-Sep;7(3):654-665. doi: 10.1177/2045893217709025. Epub 2017 Jun 8.

22.

Complications associated with the use of oral anticoagulation in patients with pulmonary arterial hypertension from two referral centers.

Roldan T, Rios JJ, Villamañan E, Waxman AB.

Pulm Circ. 2017 Jul-Sep;7(3):692-701. doi: 10.1177/2045893217721903. Epub 2017 Jul 14.

23.

Hemodynamic and metabolic characteristics associated with development of a right ventricular outflow tract pressure gradient during upright exercise.

van Riel ACMJ, Systrom DM, Oliveira RKF, Landzberg MJ, Mulder BJM, Bouma BJ, Maron BA, Shah AM, Waxman AB, Opotowsky AR.

PLoS One. 2017 Jun 21;12(6):e0179053. doi: 10.1371/journal.pone.0179053. eCollection 2017.

24.

Open label study of ambrisentan in patients with exercise pulmonary hypertension.

Segrera SA, Lawler L, Opotowsky AR, Systrom D, Waxman AB.

Pulm Circ. 2017 Apr-Jun;7(2):531-538. doi: 10.1177/2045893217709024. Epub 2017 May 12.

25.

Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure.

Waxman AB, McElderry HT, Gomberg-Maitland M, Burke MC, Ross EL, Bersohn MM, Pangarkar SS, Tarver JH, Zwicke DL, Feldman JP, Chakinala MM, Frantz RP, Thompson GB, Torres F, Rauck RL, Clagg K, Durst L, Li P, Morris M, Southall KL, Peterson L, Bourge RC.

Chest. 2017 Dec;152(6):1128-1134. doi: 10.1016/j.chest.2017.04.188. Epub 2017 Jun 3.

PMID:
28583617
26.

Invasive cardiopulmonary exercise testing in the evaluation of unexplained dyspnea: Insights from a multidisciplinary dyspnea center.

Huang W, Resch S, Oliveira RK, Cockrill BA, Systrom DM, Waxman AB.

Eur J Prev Cardiol. 2017 Jul;24(11):1190-1199. doi: 10.1177/2047487317709605. Epub 2017 May 16.

PMID:
28506086
27.

Persistence and proliferation of human mesenchymal stromal cells in the right ventricular myocardium after intracoronary injection in a large animal model of pulmonary hypertension.

Badr Eslam R, Croce K, Mangione FM, Musmann R, Leopold JA, Mitchell RN, Waxman AB.

Cytotherapy. 2017 Jun;19(6):668-679. doi: 10.1016/j.jcyt.2017.03.002. Epub 2017 Apr 6.

28.

Accuracy of Echocardiography to Estimate Pulmonary Artery Pressures With Exercise: A Simultaneous Invasive-Noninvasive Comparison.

van Riel AC, Opotowsky AR, Santos M, Rivero JM, Dhimitri A, Mulder BJ, Bouma BJ, Landzberg MJ, Waxman AB, Systrom DM, Shah AM.

Circ Cardiovasc Imaging. 2017 Apr;10(4). pii: e005711. doi: 10.1161/CIRCIMAGING.116.005711.

29.

Development of a Right Ventricular Outflow Tract Gradient During Upright Exercise: A Hemodynamic Observation.

van Riel AC, Systrom DM, Oliveira RK, Landzberg MJ, Mulder BJ, Bouma BJ, Maron BA, Shah AM, Waxman AB, Opotowsky AR.

J Am Coll Cardiol. 2017 Feb 7;69(5):595-597. doi: 10.1016/j.jacc.2016.11.039. No abstract available.

30.

Left ventricular deformation at rest predicts exercise-induced elevation in pulmonary artery wedge pressure in patients with unexplained dyspnoea.

Biering-Sørensen T, Santos M, Rivero J, McCullough SD, West E, Opotowsky AR, Waxman AB, Systrom DM, Shah AM.

Eur J Heart Fail. 2017 Jan;19(1):101-110. doi: 10.1002/ejhf.659. Epub 2016 Nov 22.

31.

Vascular stiffness mechanoactivates YAP/TAZ-dependent glutaminolysis to drive pulmonary hypertension.

Bertero T, Oldham WM, Cottrill KA, Pisano S, Vanderpool RR, Yu Q, Zhao J, Tai Y, Tang Y, Zhang YY, Rehman S, Sugahara M, Qi Z, Gorcsan J 3rd, Vargas SO, Saggar R, Saggar R, Wallace WD, Ross DJ, Haley KJ, Waxman AB, Parikh VN, De Marco T, Hsue PY, Morris A, Simon MA, Norris KA, Gaggioli C, Loscalzo J, Fessel J, Chan SY.

J Clin Invest. 2016 Sep 1;126(9):3313-35. doi: 10.1172/JCI86387. Epub 2016 Aug 22.

32.

Treprostinil Administered to Treat Pulmonary Arterial Hypertension Using a Fully Implantable Programmable Intravascular Delivery System: Results of the DelIVery for PAH Trial.

Bourge RC, Waxman AB, Gomberg-Maitland M, Shapiro SM, Tarver JH 3rd, Zwicke DL, Feldman JP, Chakinala MM, Frantz RP, Torres F, Cerkvenik J, Morris M, Thalin M, Peterson L, Rubin LJ.

Chest. 2016 Jul;150(1):27-34. doi: 10.1016/j.chest.2015.11.005. Epub 2016 Jan 13.

33.

Physiological Techniques and Pulmonary Hypertension - Left Heart Disease.

Agarwal M, Waxman AB.

Prog Cardiovasc Dis. 2016 Jul-Aug;59(1):30-41. doi: 10.1016/j.pcad.2016.05.001. Epub 2016 May 18. Review.

PMID:
27211586
34.

Exercise intolerance in pulmonary hypertension: mechanism, evaluation and clinical implications.

Babu AS, Arena R, Myers J, Padmakumar R, Maiya AG, Cahalin LP, Waxman AB, Lavie CJ.

Expert Rev Respir Med. 2016 Sep;10(9):979-90. doi: 10.1080/17476348.2016.1191353. Epub 2016 Jun 10. Review.

PMID:
27192047
35.

Pulmonary vascular morphology as an imaging biomarker in chronic thromboembolic pulmonary hypertension.

Rahaghi FN, Ross JC, Agarwal M, González G, Come CE, Diaz AA, Vegas-Sánchez-Ferrero G, Hunsaker A, San José Estépar R, Waxman AB, Washko GR.

Pulm Circ. 2016 Mar;6(1):70-81. doi: 10.1086/685081.

36.

Unexplained exertional dyspnea caused by low ventricular filling pressures: results from clinical invasive cardiopulmonary exercise testing.

Oldham WM, Lewis GD, Opotowsky AR, Waxman AB, Systrom DM.

Pulm Circ. 2016 Mar;6(1):55-62. doi: 10.1086/685054.

37.

Pulmonary haemodynamics during recovery from maximum incremental cycling exercise.

Oliveira RK, Waxman AB, Agarwal M, Badr Eslam R, Systrom DM.

Eur Respir J. 2016 Jul;48(1):158-67. doi: 10.1183/13993003.00023-2016. Epub 2016 Apr 28.

38.

Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension.

Aghamohammadzadeh R, Zhang YY, Stephens TE, Arons E, Zaman P, Polach KJ, Matar M, Yung LM, Yu PB, Bowman FP, Opotowsky AR, Waxman AB, Loscalzo J, Leopold JA, Maron BA.

FASEB J. 2016 Jul;30(7):2511-27. doi: 10.1096/fj.201500042. Epub 2016 Mar 22.

39.

Protocol for exercise hemodynamic assessment: performing an invasive cardiopulmonary exercise test in clinical practice.

Berry NC, Manyoo A, Oldham WM, Stephens TE, Goldstein RH, Waxman AB, Tracy JA, Leary PJ, Leopold JA, Kinlay S, Opotowsky AR, Systrom DM, Maron BA.

Pulm Circ. 2015 Dec;5(4):610-8. doi: 10.1086/683815. Review.

40.

Age-related upper limits of normal for maximum upright exercise pulmonary haemodynamics.

Oliveira RK, Agarwal M, Tracy JA, Karin AL, Opotowsky AR, Waxman AB, Systrom DM.

Eur Respir J. 2016 Apr;47(4):1179-88. doi: 10.1183/13993003.01307-2015. Epub 2015 Dec 17.

41.

Using Clinical Trial End Points to Risk Stratify Patients With Pulmonary Arterial Hypertension.

Waxman AB, Farber HW.

Circulation. 2015 Dec 1;132(22):2152-61. doi: 10.1161/CIRCULATIONAHA.114.012328. Review. No abstract available.

PMID:
26621638
42.

Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit.

Bertero T, Cottrill KA, Lu Y, Haeger CM, Dieffenbach P, Annis S, Hale A, Bhat B, Kaimal V, Zhang YY, Graham BB, Kumar R, Saggar R, Saggar R, Wallace WD, Ross DJ, Black SM, Fratz S, Fineman JR, Vargas SO, Haley KJ, Waxman AB, Chau BN, Fredenburgh LE, Chan SY.

Cell Rep. 2015 Nov 3;13(5):1016-32. doi: 10.1016/j.celrep.2015.09.049. Epub 2015 Oct 22.

43.

Anticoagulation in patients with pulmonary arterial hypertension: An update on current knowledge.

Roldan T, Landzberg MJ, Deicicchi DJ, Atay JK, Waxman AB.

J Heart Lung Transplant. 2016 Feb;35(2):151-64. doi: 10.1016/j.healun.2015.10.002. Epub 2015 Oct 9.

PMID:
26527532
44.

E/e' Ratio in Patients With Unexplained Dyspnea: Lack of Accuracy in Estimating Left Ventricular Filling Pressure.

Santos M, Rivero J, McCullough SD, West E, Opotowsky AR, Waxman AB, Systrom DM, Shah AM.

Circ Heart Fail. 2015 Jul;8(4):749-56. doi: 10.1161/CIRCHEARTFAILURE.115.002161. Epub 2015 Jun 11.

45.

Improving decision making for massive transfusions in a resource poor setting: a preliminary study in Kenya.

Riviello ED, Letchford S, Cook EF, Waxman AB, Gaziano T.

PLoS One. 2015 May 28;10(5):e0127987. doi: 10.1371/journal.pone.0127987. eCollection 2015.

46.

Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension.

White K, Lu Y, Annis S, Hale AE, Chau BN, Dahlman JE, Hemann C, Opotowsky AR, Vargas SO, Rosas I, Perrella MA, Osorio JC, Haley KJ, Graham BB, Kumar R, Saggar R, Saggar R, Wallace WD, Ross DJ, Khan OF, Bader A, Gochuico BR, Matar M, Polach K, Johannessen NM, Prosser HM, Anderson DG, Langer R, Zweier JL, Bindoff LA, Systrom D, Waxman AB, Jin RC, Chan SY.

EMBO Mol Med. 2015 Jun;7(6):695-713. doi: 10.15252/emmm.201404511.

47.

Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension.

Preston IR, Feldman J, White J, Franco V, Ishizawar D, Burger C, Waxman AB, Hill NS.

Pulm Circ. 2014 Sep;4(3):456-61. doi: 10.1086/677360.

48.

Central cardiac limit to aerobic capacity in patients with exertional pulmonary venous hypertension: implications for heart failure with preserved ejection fraction.

Santos M, Opotowsky AR, Shah AM, Tracy J, Waxman AB, Systrom DM.

Circ Heart Fail. 2015 Mar;8(2):278-85. doi: 10.1161/CIRCHEARTFAILURE.114.001551. Epub 2014 Dec 30.

49.

The microRNA-130/301 family controls vasoconstriction in pulmonary hypertension.

Bertero T, Cottrill K, Krauszman A, Lu Y, Annis S, Hale A, Bhat B, Waxman AB, Chau BN, Kuebler WM, Chan SY.

J Biol Chem. 2015 Jan 23;290(4):2069-85. doi: 10.1074/jbc.M114.617845. Epub 2014 Dec 12.

50.

Right heart failure: toward a common language.

Mehra MR, Park MH, Landzberg MJ, Lala A, Waxman AB.

Pulm Circ. 2013 Dec;3(4):963-7. doi: 10.1086/674750.

Supplemental Content

Loading ...
Support Center